Add like
Add dislike
Add to saved papers

The hydrogel lacrimal stent for dacryocystorhinostomy: preliminary experience.

PURPOSE: To present the results of dacryocystorhinostomy with the use of a newly designed hydrogel lacrimal stent for repair of acquired nasolacrimal duct obstruction.

METHODS: Noncomparative interventional case series. Twenty-three cases of acquired nasolacrimal duct obstruction confirmed by probing and irrigation underwent dacryocystorhinostomy using the hydrogel lacrimal stent. Tearing symptoms, functional endoscopic dye test, and anatomic appearance of ostia were noted at follow-up.

RESULTS: Five of 23 ostia closed during the postoperative period (1-3 months), translating to a late success rate of 78.3%. The 5 failed cases were treated successfully with ostium revision, 1 case requiring 2 revisions. All patients had endoscopic follow-up with a minimum follow-up of 6 months after stent removal. In the successful cases we noted a large, quiet ostium with good separation of the nasal septum and middle turbinate. Eleven cases (47.8%) had history of previously failed dacryocystorhinostomy surgery, chronic sinusitis, deviated septum, or maxillofacial surgery. There were no complications or reports of unusual pain or symptoms associated with the stent itself.

CONCLUSIONS: Early experience suggests the hydrogel lacrimal stent is a well-tolerated, effective tool for dacryocystorhinostomy surgery after acquired nasolacrimal duct obstruction. The device may serve as a useful surgical tool by holding open the ostium, maintaining apposition of the mucosal edges, and decreasing the incidence of nasal adhesions.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app